CA2521902A1 - Combinaison pharmaceutique a base d'eletriptan et de bicarbonate de sodium - Google Patents

Combinaison pharmaceutique a base d'eletriptan et de bicarbonate de sodium Download PDF

Info

Publication number
CA2521902A1
CA2521902A1 CA002521902A CA2521902A CA2521902A1 CA 2521902 A1 CA2521902 A1 CA 2521902A1 CA 002521902 A CA002521902 A CA 002521902A CA 2521902 A CA2521902 A CA 2521902A CA 2521902 A1 CA2521902 A1 CA 2521902A1
Authority
CA
Canada
Prior art keywords
eletriptan
sodium bicarbonate
migraine
pharmaceutically acceptable
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002521902A
Other languages
English (en)
Inventor
Michael John Humphrey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc.
Michael John Humphrey
Pfizer Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0308469A external-priority patent/GB0308469D0/en
Priority claimed from GB0312479A external-priority patent/GB0312479D0/en
Application filed by Pfizer Inc., Michael John Humphrey, Pfizer Limited filed Critical Pfizer Inc.
Publication of CA2521902A1 publication Critical patent/CA2521902A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002521902A 2003-04-11 2004-03-31 Combinaison pharmaceutique a base d'eletriptan et de bicarbonate de sodium Abandoned CA2521902A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0308469.6 2003-04-11
GB0308469A GB0308469D0 (en) 2003-04-11 2003-04-11 Pharmaceutical combination
GB0312479A GB0312479D0 (en) 2003-05-30 2003-05-30 Pharmaceutical combination
GB0312479.9 2003-05-30
PCT/IB2004/001115 WO2004089365A1 (fr) 2003-04-11 2004-03-31 Combinaison pharmaceutique a base d'eletriptan et de bicarbonate de sodium

Publications (1)

Publication Number Publication Date
CA2521902A1 true CA2521902A1 (fr) 2004-10-21

Family

ID=33161221

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002521902A Abandoned CA2521902A1 (fr) 2003-04-11 2004-03-31 Combinaison pharmaceutique a base d'eletriptan et de bicarbonate de sodium

Country Status (12)

Country Link
EP (1) EP1615635A1 (fr)
JP (1) JP2006522790A (fr)
AR (1) AR044009A1 (fr)
BR (1) BRPI0409127A (fr)
CA (1) CA2521902A1 (fr)
MX (1) MXPA05010070A (fr)
NL (1) NL1025908C2 (fr)
PA (1) PA8599901A1 (fr)
PE (1) PE20050086A1 (fr)
TW (1) TW200423929A (fr)
UY (1) UY28260A1 (fr)
WO (1) WO2004089365A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090299077A1 (en) * 2008-05-22 2009-12-03 Vinod Kumar Kansal Salts of (R)-5-(2phenylsulphonylethenyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole, 5-bromo-3-[(R)-1-methyl-pyrrolidin-2-ylmethyl]-1H-indole and of eletriptan
IT1393700B1 (it) 2009-04-22 2012-05-08 F S I Fabbrica Italiana Sint Sintesi di 3-{[(2r)-1-metilpirrolidin-2-il]metil}-5-[2-(fenilsulfonil)etil]-1h-indolo
JP6878021B2 (ja) * 2016-02-02 2021-05-26 第一三共ヘルスケア株式会社 トリプタンとアスコルビン酸を含有する医薬組成物
AU2019297360B2 (en) 2018-07-03 2022-07-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1197038B (it) * 1986-08-01 1988-11-25 Zambon Spa Composizione farmaceutica ad attivita' analgesica
US5607951A (en) 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
IT1272149B (it) * 1993-03-26 1997-06-11 Zambon Spa Composizione farmeceutiche ad attivita' analgesica
GB9417310D0 (en) 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
US6488961B1 (en) 1996-09-20 2002-12-03 Ethypharm, Inc. Effervescent granules and methods for their preparation
GB9704524D0 (en) * 1997-03-05 1997-04-23 Smithkline Beecham Plc Composition
GB9816556D0 (en) 1998-07-30 1998-09-30 Pfizer Ltd Therapy
GB9825988D0 (en) 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
IL136025A0 (en) * 1999-05-14 2001-05-20 Pfizer Prod Inc Combination therapy for the treatment of migraine
GB0018968D0 (en) 2000-08-02 2000-09-20 Pfizer Ltd Particulate composition
GB0105131D0 (en) * 2001-03-01 2001-04-18 Pfizer Ltd Compositions having improved bioavailability
GB0129117D0 (en) * 2001-12-05 2002-01-23 Glaxo Group Ltd Pharmaceutical composition
JP2006523620A (ja) * 2003-02-19 2006-10-19 バイオヴェイル ラボラトリーズ インコーポレイテッド 急速吸収選択的５−ｈｔ作用剤製剤

Also Published As

Publication number Publication date
EP1615635A1 (fr) 2006-01-18
MXPA05010070A (es) 2005-11-23
WO2004089365A1 (fr) 2004-10-21
PA8599901A1 (es) 2005-02-04
UY28260A1 (es) 2004-11-30
AR044009A1 (es) 2005-08-24
NL1025908A1 (nl) 2004-10-13
TW200423929A (en) 2004-11-16
BRPI0409127A (pt) 2006-03-28
NL1025908C2 (nl) 2005-11-22
PE20050086A1 (es) 2005-03-01
JP2006522790A (ja) 2006-10-05

Similar Documents

Publication Publication Date Title
JP5344620B2 (ja) オルメサルタンメドキソミル及びアムロジピンの固形製剤
US8012503B2 (en) Method of enhancing absorptions of transmucosal administration formulations
US20050187262A1 (en) Compositions comprising (S)-amlodipine and an angiotensin receptor blocker and methods of their use
JP2003522145A (ja) セントラルカンナビノイドレセプター拮抗剤のタバコ消費を止める助けに有用である医薬品への使用
JP2006527195A (ja) トリプタンおよびｎｓａｉｄを含む組成物
EP3320903A1 (fr) Composition pharmaceutique contenant l'amlodipine, le valsartan et la rosuvastatine
US5468504A (en) Effervescent pharmaceutical compositions
KR100591237B1 (ko) 5ｈｔ1 수용체 작용제를 포함하는 제약 조성물
US20040204475A1 (en) Pharmaceutical combination
BG65309B1 (bg) Използване на елетриптан за профилактика на мигренозен рецидив
AU2011339150B2 (en) Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof
CA2521902A1 (fr) Combinaison pharmaceutique a base d'eletriptan et de bicarbonate de sodium
JP2002255814A (ja) アスピリンを含有する医薬組成物
US9675551B2 (en) Sublingual pharmaceutical composition containing an antihistamine agent and method for the preparation thereof
JPH0678233B2 (ja) 抗高血圧症および心臓保護作用を有する医薬調剤
JP2009535336A (ja) 片頭痛治療用の固定組合せ剤形
KR100188172B1 (ko) 제약 조성물
US20220287973A1 (en) Orodispersible powder composition comprising a triptan
EP2246046A1 (fr) Comprimé d'olanzapine à désintégration orale
TR2021020750A2 (tr) Oral yolla dağilan di̇klofenak ve eletri̇ptan kombi̇nasyonu
US20100179202A1 (en) Orally disintegrating composition of zolmitriptan
GB2471970A (en) Composition comprising olmesartan medoxomil, amlodipine and hydrochlorothiazide
JP2009234946A (ja) 併用医薬

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead